If you want to effectively promote clinical trials at the local level, “don’t wait to reach out to your community [until] you need something,” says John Stewart, MD, chief and associate professor of surgery with the Durham Veterans Administration Hospital of Duke University.
Instead, connect with your community proactively over broad health issues such as gun violence or childhood trauma, Stewart told attendees of a panel discussion at the Clinical Trial Collaborations conference in Cambridge, Mass., on April 11. “The community is a big, big driver,” he emphasized. However, there are no shortcuts when it comes to building trust in a community, he said. “It takes a lot of sweat equity.”
It’s vital to conduct the work at the grassroots level, Stewart and other panelists said. Many communities are wary, or ignorant when it comes to clinical trials. Overly complex informed consent practices and a perceived opaque use of data generated by trials are two of the more onerous factors to overcome, Stewart said.
It’s incumbent on local clinical trial professionals to work toward a “sincere and genuine presence” in the local community, said Murray Abramson, MD, vice president for global clinical operations with Biogen. It’s a key to building credibility and collaboration, he and other panelists agreed.
Novel Techniques for Improving Clinical Trial Subject Retention – Join recruitment expert Nicki Norris, MBA, Chief Executive Officer, Symphony Clinical Research, at ACRP 2018 to explore some of the many reasons more than 85% of clinical trials fail to retain enough patients. Hear innovative approaches for improving subject retention and learn about metrics demonstrating the impact of in-home and alternate site clinical services on patients, sites, and study sponsors. Take home strategies to immediately improve subject retention numbers. View Session Details
Patient voices are increasingly influential with regulators and payers, Abramson said. Patients are also having a growing impact on the medical scientific community. Patients are calling for trials that demonstrate clear benefit to them, and that’s a demand that should be kept front of mind throughout the clinical trial life cycle, Abramson added.
There’s another interesting trend at work, according to Jeff James, CEO of Wilmington Health. “We’re seeing trial participation less driven by [principal investigators (PIs)], and more by primary care physicians,” he said. Even if the physicians don’t want to be PIs, “they are becoming more and more vocal about learning what trials are coming that might be of benefit to their set of patients. That’s a very positive thing.”
Author: Michael Causey
Free with Your ACRP Membership: Using Metrics to Improve Subject Recruitment and Retention
Overcome challenges in subject recruitment and retention by learning how to leverage the metrics critical to success with this on-demand eLearning course – now FREE with your ACRP Membership.
Low subject recruitment and retention are a leading cause of trial delays and failure, but using the right metrics at the right time can help clinical study sites pinpoint areas for improvement and subsequently assess those improvements.
Learn which essential measures you should use for every trial in order to benchmark and monitor improvements in specific areas of subject recruitment, accrual and retention.
This self-paced eLearning course will equip site personnel to assess current site performance and readiness for action, and to implement appropriate metric measurement and monitoring.